Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Steenbruggen TG, Bouwer NI, Smorenburg CH, Rier HN, Jager A, Beelen K, Ten Tije AJ, de Jong PC, Drooger JC, Holterhues C, Kitzen JJEM, Levin M-, Sonke GS.

Breast Cancer Res Treat. 2019 Dec;178(3):597-605. doi: 10.1007/s10549-019-05427-1. Epub 2019 Sep 6.

PMID:
31493033
2.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cort├Ęs J, Caldas C, Linn SC.

Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22.

PMID:
31439579
3.

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, van Vlierberghe RLP, Blok EJ, Giardiello D, Sanders J, Van de Vijver K, Horlings HM, Kuppen PJK, Linn SC, Schmidt MK, Kok M.

Breast Cancer Res. 2019 Aug 7;21(1):90. doi: 10.1186/s13058-019-1176-2.

4.

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.

Kruger DT, Beelen KJ, Opdam M, Sanders J, van der Noort V, Boven E, Linn SC.

Br J Cancer. 2018 Oct;119(7):832-839. doi: 10.1038/s41416-018-0221-8. Epub 2018 Oct 5.

5.

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J, Sanders J, Vermorken J, van Diest P, Linn S.

BMC Cancer. 2018 Jul 24;18(1):761. doi: 10.1186/s12885-018-4516-1.

6.

[Relapse of chronic inflammatory demyelinating polyneuropathy following treatment with zoledronic acid].

Loef M, Geijteman ECT, Beelen KJ, Bornebroek M, Schweitzer DH.

Ned Tijdschr Geneeskd. 2017;161:D1747. Dutch.

PMID:
29125079
7.

Measuring Emotion in Parliamentary Debates with Automated Textual Analysis.

Rheault L, Beelen K, Cochrane C, Hirst G.

PLoS One. 2016 Dec 22;11(12):e0168843. doi: 10.1371/journal.pone.0168843. eCollection 2016.

8.

St. Gallen endocrine response classes predict recurrence rates over time.

Koornstra RH, Beelen KJ, Vincent AD, van der Noort V, van Diest PJ, Linn SC.

Breast. 2015 Dec;24(6):705-12. doi: 10.1016/j.breast.2015.08.009. Epub 2015 Oct 1.

PMID:
26429398
9.

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

Bentin Toaldo C, Alexi X, Beelen K, Kok M, Hauptmann M, Jansen M, Berns E, Neefjes J, Linn S, Michalides R, Zwart W.

BMC Cancer. 2015 Aug 14;15:588. doi: 10.1186/s12885-015-1591-4.

10.

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.

Beelen K, Hoefnagel LD, Opdam M, Wesseling J, Sanders J, Vincent AD, van Diest PJ, Linn SC.

Int J Cancer. 2014 Sep 1;135(5):1257-63. doi: 10.1002/ijc.28769. Epub 2014 Feb 27.

11.

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.

12.

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 21;16(1):R6. doi: 10.1186/bcr3598.

13.

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5.

14.

Tamoxifen resistance: from bench to bedside.

Droog M, Beelen K, Linn S, Zwart W.

Eur J Pharmacol. 2013 Oct 5;717(1-3):47-57. doi: 10.1016/j.ejphar.2012.11.071. Epub 2013 Mar 29. Review.

PMID:
23545365
15.

Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?

Beelen K, Zwart W, Linn SC.

Nat Rev Clin Oncol. 2012 Sep;9(9):529-41. doi: 10.1038/nrclinonc.2012.121. Epub 2012 Jul 24. Review.

PMID:
22825374
16.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

Cancer Cell. 2007 Oct;12(4):395-402.

17.

[Nipple secretion: a concern for the family physician?].

van Beelen KJ, Welvaart K.

Ned Tijdschr Geneeskd. 1991 Nov 16;135(46):2171-3. Dutch. No abstract available.

PMID:
1956443

Supplemental Content

Loading ...
Support Center